Many drugmakers rang in the new year with increases in list prices of dozens of drugs that will take effect in 2018.
Many drugmakers rang in the new year with increases in list prices of dozens of drugs that will take effect in 2018. Early data suggest the increases generally remained within a 10% self-imposed limit that was popularized by Allergan’s chief executive, Brent Saunders, in 2016, when he pledged to keep price rises below the 10% figure as part of what he called the company’s “social contract with patients.”
Saunders’ pricing promise may have become something of a de facto price pledge for many companies, one that was made in response to Mylan’s price hike on Epipen auto-injectors, which set off a public controversy. Pfizer has been a notable exception to the voluntary 10% price cap pledge. In 2017, Pfizer raised US prices on close to 100 of its drugs by an average of 20%.
Amgen raised the price of its reference etanercept (Enbrel), its blockbuster rheumatoid arthritis and psoriasis treatment, by 9.7%, and also raised the price of its pegfilgrastim (Neulasta) by 4.9%. An FDA approved biosimilar etanercept, Erelzi, has not yet launched in the United States.
Specialty pharma companies Allergan, Teva, Collectis, Insys, Synergy, and Supernus all raised prices effective January 1. Allergan raised prices on 18 different medications by 9.5%—just below its self-imposed limit—including its hypertension treatment Bystolic, dry eye treatment Restasis (which was the subject of considerable controversy in 2017), irritable bowel syndrome treatment Linzess, and Alzheimer’s treatment Namenda XR. An Allergan company spokesman said that these increases will be the only ones taken on those brands in 2018, and he noted that discounts to payers should bring actual increases to consumers down to the low single digits—approximately 2% to 3%.
Teva increased prices on 7 of its drugs, focusing on its branded products including Azilect, its Parkinson’s treatment, and the ProAir HFA and ProAir RespiClick asthma inhalers, which went up by 6% and 3%, respectively. Teva’s price increases overall range from 2.3% to 9.4%. The price hikes come as Teva has publicized plans to lay off 14,000 of its employees, setting off social unrest in Israel, where the layoffs will hit particularly hard.
The biopharmaceutical company Horizon Pharma kept price hikes on 4 of its drugs at 9.9%.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.